Trial Profile
Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naive to Pneumococcal Vaccine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2019
Price :
$35
*
At a glance
- Drugs NBP 606 (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors SK Chemicals
- 26 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 24 Mar 2014 New trial record